Associate Chief Physician
Specialties: Diagnosis and treatment of gastrointestinal tumors, including esophageal cancer, gastric cancer, colorectal cancer, hepatobiliary and pancreatic tumors, neuroendocrine tumors, gastrointestinal stromal tumors, etc. Participated in multiple international and domestic multicenter clinical studies of drugs or comprehensive therapies.
Representative Achievements:
- National Natural Science Foundation of China, Major Research Program, Grant No. 92159106, Establishment of a Precision Evaluation Model for Tertiary Lymphoid Structures in Esophageal Squamous Cell Carcinoma and Exploration of Its Guiding Role in Immunotherapy, 2022‑01‑01 to 2024‑12‑31, 600,000 RMB, Grant Period Completed, Participant
- Y. Cao; S. Qin; S. Luo; Z. Li; Y. Cheng; Y. Fan; Y. Sun; X. Yin; X. Yuan; W. Li; T. Liu; C.-H. Hsu; X. Lin; S.-B. Kim; T. Kojima; J. Zhang; S.-H. Lee; Y. Bai; K. Muro; T. Doi; C. Bai; K. Gu; H.-M. Pan; L. Bai; J.-W. Yang; Y. Cui; W. Lu; J. Chen; Pembrolizumab versus chemotherapy for patients with esophageal squamous cell carcinoma enrolled in the randomized KEYNOTE‑181 trial in Asia, ESMO Open, 2022, 7(1): 100341 (Journal Article) (Author’s Note: Sole first author, sole corresponding author)
- Yanshuo Cao; Ming Lu; Yu Sun; Jifang Gong; Jie Li1; Zhihao Lu; Jian Li; Xiaotian Zhang; Yan Li; Zhi Peng; Jun Zhou; Xicheng Wang; Lin Shen; Surufatinib plus toripalimab in patients with advanced solid tumors: a single‑arm, open‑label, phase 1 trial, Journal of Cancer Research and Clinical Oncology, 2022, 149(2023): 779‑789 (Journal Article) (Author’s Note: Co‑first author)
English